OSAM
CTMX icon

O'Shaughnessy Asset Management’s CytomX Therapeutics CTMX Stock Holding History

O'Shaughnessy Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-9,570
Closed -$175K – 937
2018
Q3 		$175K Hold
9,570
– – ﹤0.01% 572
2018
Q2 		$217K Hold
9,570
– – ﹤0.01% 519
2018
Q1 		$272K Buy
+9,570
New +$273K 0.01% 456

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

O'Shaughnessy Asset Management's CTMX Position: Q4 2018 in Review

O'Shaughnessy Asset Management sold out of CytomX Therapeutics (CTMX) in Q4 2018, closing a stake of 9,570 shares — an estimated $175K sold.

O'Shaughnessy Asset Management first reported a position in CTMX in Q1 2018 and held it in 3 quarters. The position peaked at $272K in Q1 2018. 111 funds tracked by Wall St. Rank hold CTMX as of Q4 2018.

  • O'Shaughnessy Asset Management reported no remaining CytomX Therapeutics position as of Q4 2018 after selling out during the quarter.
  • O'Shaughnessy Asset Management sold 9,570 CytomX Therapeutics shares in Q4 2018, an estimated $175K.
  • O'Shaughnessy Asset Management first reported a position in CytomX Therapeutics in Q1 2018 and held it in 3 quarters.
  • O'Shaughnessy Asset Management's CytomX Therapeutics position peaked at $272K in Q1 2018.
  • 111 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2018.

Based on O'Shaughnessy Asset Management's 13F filing for Q4 2018, filed 12 Feb 2019.